Cargando…

Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma

The aim of this study was to identify the relationships of epidermal growth factor receptor (EGFR) mutations and anaplastic large-cell lymphoma kinase (ALK) status with CT characteristics in adenocarcinoma using the largest patient cohort to date. In this study, preoperative chest CT findings prior...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Xiaoyu, Fan, Jun, Li, Yumin, Cao, Yukun, Gu, Jin, Jia, Xi, Wang, Yuhui, Shi, Heshui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952563/ https://www.ncbi.nlm.nih.gov/pubmed/33707479 http://dx.doi.org/10.1038/s41598-021-83646-7

Ejemplares similares

CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas
por: Han, Xiaoyu, et al.
Publicado: (2020)

Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status
por: Han, Xiaoyu, et al.
Publicado: (2020)

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
por: Fan, Jun, et al.
Publicado: (2020)

Value of combining PET/CT and clinicopathological features in predicting EGFR mutation in Lung Adenocarcinoma with Bone Metastasis
por: Yao, Guangyu, et al.
Publicado: (2020)

The Value of CT-Based Radiomics for Predicting Spread Through Air Spaces in Stage IA Lung Adenocarcinoma
por: Han, Xiaoyu, et al.
Publicado: (2022)

Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis
por: Cao, Yajuan, et al.
Publicado: (2019)

Cytologic Features of ALK-Positive Pulmonary Adenocarcinoma
por: Ha, Seung Yeon, et al.
Publicado: (2013)

Six-Month Follow-up Chest CT findings after Severe COVID-19 Pneumonia
por: Han, Xiaoyu, et al.
Publicado: (2021)

Quantitative inspiratory–expiratory chest CT findings in COVID-19 survivors at the 6-month follow-up
por: Jia, Xi, et al.
Publicado: (2022)

ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma
por: Mao, Yanjiao, et al.
Publicado: (2017)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas
por: Woo, Jung Han, et al.
Publicado: (2020)

Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Marino, Federica Zito, et al.
Publicado: (2015)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

Radiological and Clinical Features and Outcomes of Patients with Primary Pulmonary Salivary Gland-Type Tumors
por: Han, Xiaoyu, et al.
Publicado: (2019)

Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma
por: Li, Pupu, et al.
Publicado: (2019)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Zito Marino, Federica, et al.
Publicado: (2015)

Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis
por: Tfayli, Arafat, et al.
Publicado: (2017)

Longitudinal Assessment of Chest CT Findings and Pulmonary Function after COVID-19 Infection
por: Han, Xiaoyu, et al.
Publicado: (2023)

Assessment of regional left ventricular myocardial strain in patients with left anterior descending coronary stenosis using computed tomography feature tracking
por: Han, Xiaoyu, et al.
Publicado: (2020)

Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations
por: Kim, Ho Cheol, et al.
Publicado: (2019)

Chest CT Imaging Features of Typical Covert COVID-19 Cases
por: Dai, Meng, et al.
Publicado: (2021)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
por: Lee, Ki-Chang, et al.
Publicado: (2021)

Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction
por: Li, Yumin, et al.
Publicado: (2021)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

CT-guided aspiration lung biopsy for EGFR and ALK gene mutation analysis of lung cancer
por: Lian, Weisheng, et al.
Publicado: (2017)

Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
por: Kedia, Shiksha, et al.
Publicado: (2015)

Prognostic value of baseline clinical and HRCT findings in 101 patients with severe COVID-19 in Wuhan, China
por: Cao, Yukun, et al.
Publicado: (2020)

CT screening for early diagnosis of SARS-CoV-2 infection – Authors' reply
por: Shi, Heshui, et al.
Publicado: (2020)

The predictive value of (18)F-FDG PET/CT in an EGFR-mutated lung adenocarcinoma population
por: Wang, Jian, et al.
Publicado: (2022)

Breast metastasis from EGFR/ALK negative lung adenocarcinoma: A case report
por: Cao, Liyu, et al.
Publicado: (2020)

Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report
por: Leung, Jackson Ka Chun, et al.
Publicado: (2023)

Value of (18)F–FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients
por: Lv, Zhilei, et al.
Publicado: (2017)

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
por: Kim, Hyungjin, et al.
Publicado: (2017)

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
por: Kim, Hyungjin, et al.
Publicado: (2019)

Sequential EGFR mutation and ALK rearrangement in adenocarcinoma lung, with rare metastasis to bilateral breast, ovary and endometrium
por: Anjali, V.R., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_donuuvuvbs8tvvvdraqa22gpd1